Skip to main content

Ovarian Cancer

Final Rule Regarding Copay Accumulator Programs May Increase Patients’ Out-of-Pocket Costs for Oral Cancer Drugs

Medicare Proposes Legislative Changes to Protected Drug Classes, Including Antineoplastics

Federal Oral Parity Legislation for Anticancer Drugs Awaits Action from Senate

Understanding Medicare Part D Prescription Drug Coverage Changes for 2020

The Experiences of Women with Ovarian Cancer: From the First Symptoms Through Repeated Courses of Chemotherapy

PARP Inhibitor Therapy Improves Outcomes for Ovarian Cancer Patients Who Have BRCA Wild-Type Tumors

Oral Medications Pose Challenges for Cancer Treatment But There Are Strategies for Improving Patient Adherence

Changes to Medicare Part D in 2020 and What They Mean for Patients with Cancer

The Burden of Ovarian Cancer Affects Multiple Dimensions of Women’s Lives

The Epidemiology of Ovarian Cancer: Different Prognoses for Different Populations

9
10
11
12
13

Page 12 of 13
Results 111 - 120 of 125